Alzamend Neuro Inc

Company Profile

Alzamend Neuro Inc had its IPO on 2021-06-15 under the ticker symbol ALZN.

The company operates in the Healthcare sector and Biotechnology industry. Alzamend Neuro Inc has a staff strength of 4 employees.

Stock update

Shares of Alzamend Neuro Inc opened at $0.23 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.23 - $0.25, and closed at $0.23.

This is a +1.32% increase from the previous day's closing price.

A total volume of 208,608 shares were traded at the close of the day’s session.

In the last one week, shares of Alzamend Neuro Inc have slipped by -16.3%.

Alzamend Neuro Inc's Key Ratios

Alzamend Neuro Inc has a market cap of $52.55 million, indicating a price to book ratio of 11.6318 and a price to sales ratio of 0.

In the last 12-months Alzamend Neuro Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-12315986. The EBITDA ratio measures Alzamend Neuro Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Alzamend Neuro Inc’s operating margin was 0% while its return on assets stood at -63.04% with a return of equity of -115.43%.

In Q3.3333333333333, Alzamend Neuro Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Alzamend Neuro Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-0.13 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Alzamend Neuro Inc’s profitability.

Alzamend Neuro Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -7.0897. Its price to sales ratio in the trailing 12-months stood at 0.

Alzamend Neuro Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$10.42 million

Total Liabilities

$1.64 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Alzamend Neuro Inc ended 2025 with $10.42 million in total assets and $0 in total liabilities. Its intangible assets were valued at $10.42 million while shareholder equity stood at $8.79 million.

Alzamend Neuro Inc ended 2025 with $0 in deferred long-term liabilities, $1.64 million in other current liabilities, 9549.00 in common stock, $-35341560.00 in retained earnings and $0 in goodwill. Its cash balance stood at $9.18 million and cash and short-term investments were $9.18 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Alzamend Neuro Inc’s total current assets stands at $10.33 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $648119.00 and inventory worth $0.

In 2025, Alzamend Neuro Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Alzamend Neuro Inc paid $0 in dividends in 2025.

Other key metrics

Current Trading Price

$0.23

52-Week High

$1.5

52-Week Low

$0.49

Analyst Target Price

$7

Alzamend Neuro Inc stock is currently trading at $0.23 per share. It touched a 52-week high of $1.5 and a 52-week low of $1.5. Analysts tracking the stock have a 12-month average target price of $7.

Its 50-day moving average was $0.39 and 200-day moving average was $0.57 The short ratio stood at 3.23 indicating a short percent outstanding of 0%.

Around 4166.5% of the company’s stock are held by insiders while 723.6% are held by institutions.